Drug
Befotertinib
Befotertinib is a pharmaceutical drug with 6 clinical trials. Currently 5 active trials ongoing.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
5(83%)
Phase Distribution
Ph phase_2
5
83%
Ph phase_4
1
17%
Phase Distribution
0
Early Stage
5
Mid Stage
1
Late Stage
Phase Distribution6 total trials
Phase 2Efficacy & side effects
5(83.3%)
Phase 4Post-market surveillance
1(16.7%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
5
trials recruiting
Total Trials
6
all time
Status Distribution
Active(6)
Detailed Status
Recruiting4
Not yet recruiting1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
5
Success Rate
N/A
Most Advanced
Phase 4
Trials by Phase
Phase 25 (83.3%)
Phase 41 (16.7%)
Trials by Status
not_yet_recruiting117%
recruiting467%
active_not_recruiting117%
Recent Activity
5 active trials
Showing 5 of 6
not_yet_recruitingphase_2
ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy
NCT07410611
recruitingphase_2
Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
NCT07181499
recruitingphase_2
Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC
NCT06863506
active_not_recruitingphase_2
Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer
NCT05007938
recruitingphase_4
Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients
NCT06561620
Clinical Trials (6)
Showing 6 of 6 trials
NCT07410611Phase 2
ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy
NCT07181499Phase 2
Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
NCT06863506Phase 2
Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC
NCT05007938Phase 2
Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer
NCT06561620Phase 4
Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients
NCT06517953Phase 2
Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6